Use of Osteoporosis Medications in Older Nursing Facility Residents

Journal of the American Medical Directors Association

Volumn 8, Issue 7, 2007, Pages 453-457

  Wright, Rollin M ^a  

^a SCHOOL OF MEDICINE   (United States)

Author keywords

aged; drug utilization; nursing home; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG INDICATION; DRUG USE; EPIDEMIOLOGICAL DATA; FEMALE; FRAGILITY FRACTURE; GENDER; HEALTH STATUS; HUMAN; INDEPENDENT VARIABLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEGRO; NURSING HOME; NURSING HOME PATIENT; OSTEOPOROSIS; OUTCOME ASSESSMENT; PREVALENCE; RACE; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; TREATMENT INDICATION; UNITED STATES;

EID: 34548425595     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2007.04.002     Document Type: Article

References (60)

1. Zimmerman S.I., Girman C.J., Buie V.C., et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 9 (1999) 151-157
2. Chandler J.M., Zimmerman S.I., Girman C.J., et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 284 (2000) 972-977
3. Cali C.M., Kiel D.P., et al. An epidemiologic study of fall-related fractures among institutionalized older people. J Am Geriatr Soc 43 (1995) 1336-1340
4. Girman C.J., Chandler J.M., Zimmerman S.I., et al. Prediction of fracture in nursing home residents. J Am Geriatr Soc 50 (2002) 1341-1347
5. Colón-Emeric C.S., Pieper C.F., and Artz M.B. Can historical and functional risk factors be used to predict fractures in community-dwelling older adults?. Development and validation of a clinical tool. Osteoporos Int 13 (2002) 955-961
6. Fink H., Wyman J., Hanlon J.T., and Falls. Brocklehurst's Textbook of Geriatric Medicine. In: Tallis R., and Fillit H. (Eds). The lymphatic system. 6th ed. (2003), Churchill Livingstone, London, UK 1337-1346
7. Cooper C., Atkinson E.J., Jacobsen S.J., et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137 (1993) 1001-1005
8. Magaziner J., Lydick E., Hawkes W., et al. Excess mortality attributable to hip fracture in white women aged 70 and older. Am J Public Health 87 (1997) 1630-1636
9. Koot V.C., Peeters P.H., de Jong J.R., et al. Functional results after treatment of hip fracture: A multicentre, prospective study in 215 patients. Eur J Surg 166 (2000) 480-485
10. Brenneman S.K., Barrett-Connor E., Sajjan S., et al. Impact of recent fracture on health-related quality of life in post-menopausal women. J Bone Miner Res 21 (2006) 809-816
11. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327 (1992) 1637-1642
12. Sato Y., Iwamoto J., Kanoko T., et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165 (2005) 1743-1748
13. Sato Y., Iwamoto J., Kanoko T., et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64 (2005) 811-816
14. Kamel H.K., Hussain M.S., Tariq S., et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 109 (2000) 326-328
15. Bahl S., Coates P.S., and Greenspan S.L. The management of osteoporosis following hip fracture: Have we improved our care?. Osteoporos Int 14 (2003) 884-888
16. Jachna C.M., Shireman T.I., Whittle J., et al. Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers. J Am Geriatr Soc 53 (2005) 1275-1281
17. Bernabei R., Gambassi G., Lapane K., et al. Characteristics of the SAGE database: A new resource for research on outcomes in long-term care. Design and population characteristics of the SAGE database. J Gerontol A Biol Sci Med Sci 54A (1999) M25-M33
18. Gambassi G., Landi F., Peng L., et al., SAGE Study Group. Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. Med Care 36 (1998) 167-179
19. Long Term Care Facility Resident Assessment Instrument User's Manual, version 2.0 (1995), Health Care Financing Administration, Baltimore, MD
20. Morris J.N., Hawes C., Fries B.E., et al. Designing the national resident assessment instrument for nursing homes. Gerontologist 30 (1990) 293-307
21. Morris J.N., Nonemaker S., Murphy K., et al. A commitment to change: revisions of HCFA's RAI. J Am Geriatr Soc 45 (1997) 1011-1016
22. Hawes C., Morris J.N., Philips C.D., et al. Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS). Gerontologist 35 (1995) 172-178
23. Mor V., Banco K., Fleishman J., et al. The structure of social engagement among nursing home residents. J Gerontol B Psychol Sci Soc Sci 50 (1995) P1-P8
24. Sgadari A., Morris J.N., Fries B.E., et al. Efforts to establish the reliability of the Resident Assessment Instrument. Age Ageing 26S (1997) 27-30
25. Phillips C., Morris J.N., Hawes C., et al. Association of the Resident Assessment Instrument (RAI) with changes in function, cognition, and psychosocial status. J Am Geriatr Soc 45 (1997) 986-993
26. Morris J.N., Fries B.E., Mehr D.R., et al. MDS Cognitive Performance Scale. J Gerontol 49 (1994) M174-M182
27. Hartmaier S.L., Sloane P.D., Guess H.A., et al. Validation of the Minimum Data Set Cognitive Performance Scale: Agreement with the Mini Mental Status Examination. J Gerontol A Biol Sci Med Sci 50 (1995) M128-M133
28. Frederiksen K., Tariot P., and DeJonghe E. Minimum Data Set (MDS+) scores compare with scores from five rating scales. J Am Geriatr Soc 44 (1996) 305-307
29. Lawton M.P., Casten R., Parmelee P.A., et al. Psychometric characteristics of the minimum data set. J Am Geriatr Soc 46 (1998) 736-744
30. Master Drug Database: Documentation Manual (1995), Medispan, Inc, Indianapolis, IN
31. Osteoporosis Prevention, Diagnosis, and Therapy: NIH Consensus Statement 2000 March 27-29; 17(1):1-45. *The original document by the NIH specifically states that citations must not provide authorship attributions.
32. AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, with Selected Updates for 2003. Endocrine Practice 9 (2003) 544-564
33. Colón-Emeric C.S., Biggs D.P., Schenck A.P., et al. Risk factors for hip fracture in skilled nursing facilities: Who should be evaluated?. Osteoporos Int 14 (2003) 484-489
34. Bohannon A., Hanlon J.T., Landerman L.R., et al. Relationship between race and other potential risk factors and nonvertebral fractures in community dwelling elderly women. Am J Epidemiol 149 (1999) 1002-1009
35. Cumming R.G., and Klineberg R.J. Fall frequency and characteristics and the risk of hip fractures. J Am Geriatr Soc 42 (1994) 774-778
36. Hui S.L., Slemenda C.W., and Johnston C.C. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 111 (1989) 355-361
37. Kiely D.K., Kiel D.P., Burrows A.B., et al. Identifying nursing home residents at risk for falling. J Am Geriatr Soc 46 (1998) 551-555
38. Norton R., Campbell A.J., Reid I.R., et al. Residential status and risk of hip fracture. Age Ageing 28 (1999) 135-139
39. Wolinsky-Friedland M. Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am 24 (1995) 395-420
40. Churesigaew S., Ruvalcaba R.H., and Kelley V.C. Epilepsy and abnormal calcium metabolism in institutionalized mentally retarded patients. Am J Ment Defic 79 (1975) 738-741
41. Cohen A., Lancman M., Mogul H., et al. Strategies to protect bone mass in the older patient with epilepsy. Geriatrics 52 (1997) 70 75-78, 81
42. Nelson-Piercy C. Hazards of heparin: Allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 11 (1997) 489-509
43. Schneider D.L., Barrett-Connor E.L., and Morton D.J. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. JAMA 271 (1994) 1245-1249
44. Kleinbaum D.G., Kupper L.L., and Muller K.E. Applied Regression Analysis and Other Multivariable Methods. 2nd ed. (1988), PWS-Kent Co, Boston 497-512
45. Overgaard K., Hansen M.A., Jensen S.B., et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ 305 (1992) 556-561
46. Chesnut C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109 (2000) 267-276
47. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 (1995) 1437-1443
48. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
49. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
50. Kamel H.K. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. J Am Med Dir Assoc 5 (2004) 98-100
51. Hamid Z., Riggs A., Spencer T., et al. Vitamin D deficiency in residents of academic long-term care facilities despite having been prescribed vitamin D. J Am Med Dir Assoc 8 (2007) 71-75
52. Drinka P.J., Krause P.F., Nest L.J., et al. Determinants of vitamin D levels in nursing home residents. J Am Med Dir Assoc 8 (2007) 76-79
53. Morley J. Should all long-term care residents receive vitamin D?. J Am Med Dir Assoc 8 (2007) 69-70
54. Munir J., Wright R.J., and Carr D.B. A quality improvement study on calcium and vitamin D supplementation in long-term care. J Am Med Dir Assoc 7 (2006) 305-309
55. Redelmeier D.A., Tan S.H., and Booth G.L. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 338 (1998) 1516-1520
56. American Medical Directors Association (AMDA). Osteoporosis (2003), American Medical Directors Association (AMDA), Columbia (MD) 1-24
57. Saliba D., Solomon D., Rubenstein L., et al. Quality indicators for the management of medical conditions in nursing home residents. J Am Med Dir Assoc 5 (2004) 297-309
58. Rossouw J.E., Anderson G.L., Prentice R.L., and Writing Group for the Women's Health Initiative Investigators. Risks plus benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
59. Black D.M., Greenspan S.L., Ensrud K.E., et al., PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 (2003) 1207-1215
60. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322